Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HCM vs BMM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HCM Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–0 Matrix Metrics)

HCM Overall Winner 6-Pillar Tally: HCM 5 – 0 BMM (1 Tie) Matrix Metrics: HCM 8 – 0 BMM

As of Nov 20, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over BMM (BMM) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HCM carries a Unified Composite Score of 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin), whereas BMM carries 38.2/100 (SELL) at $2.50 (N/M Forward P/E, N/A operating margin).

  • Defensive Composite Rating Caution: Although HCM compares more favorably head-to-head, both HCM (38.1/100 SELL) and BMM (38.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: HCM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.5); meanwhile BMM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HCM vs BMM
HCM NASDAQ Head-to-Head Winner
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
$13.22
-1.71% 1D
Market Cap $2.3B
TTM Revenue $549M
Forward P/E N/M
Beta / 30D Vol 0.64β · 45% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 31.0 Fund 44.0 Flow 50.0 Mom 56.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $14.15 · SMA50: $14.11
BMM US Equity
BMM
Institutional Equity
$2.50
-8.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.19β · 100% Vol
Unified Composite Score
38.2 / 100 SELL
Tech 25.0 Fund 39.0 Flow 50.0 Mom 34.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.9%), weak momentum, RSI 26
RSI-14: 25.8 · SMA20: $3.40 · SMA50: $4.28

6-Pillar Scorecard Institutional Category Breakdown (HCM 5 – 0 BMM)

Columns: Metric · HCM · BMM
1. Valuation Multiples HCM
Forward P/E N/M N/M
Trailing P/E 134.0x N/M
PEG Ratio N/M N/M
EV / Revenue 4.2x N/M
2. Growth & Scale HCM
Revenue Growth (YoY) +0.2% N/A
Earnings Growth (YoY) -96.5% N/A
TTM Revenue (USD) $549M N/A
Market Cap $2.3B N/A
3. Profitability & Quality HCM
Gross Margin 13.3% N/A
Operating Margin -6.3% N/A
Net Profit Margin 3.3% N/A
Return on Equity (ROE) 1.5% N/A
4. Balance Sheet & Cash Flow HCM
Cash Generation (TTM) -$21M EBITDA N/A
Cash Flow Margin -3.7% EBITDA Mgn N/A
Net Cash / Leverage $7.25 Book/Sh · 1.5% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 82.7% (73rd %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat HCM
OpEx & R&D Intensity 19.6% of Rev ($108M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HCM (8) vs BMM (0)
Institutional Metric HCM BMM Criterion Row Edge
Market Capitalization
Scale
$2.3B N/A Larger Scale HCM
Trailing P/E Ratio
Valuation
134.0x N/M Lower Multiple HCM
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.2% N/A Higher Growth HCM
Operating Margin (TTM)
Profitability
-6.3% N/A Higher Margin HCM
Net Profit Margin
Profitability
3.3% N/A Higher Margin HCM
Return on Equity (ROE)
Capital Efficiency
1.5% N/A Higher ROE HCM
52-Week Range Position
Momentum
53% ($10–$16) 0% ($2–$9) Stronger Trend HCM
Beta / 30D Volatility
Risk Regime
0.64β · 45% Vol 2.19β · 100% Vol Lower Realized Risk HCM
Unified Institutional Score
Composite Signal
38.1 / 100 (SELL) 38.2 / 100 (SELL) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$549M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
13.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA ($7.25 Book/Sh · 1.5% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HCM +29.13 pp
HCM: -7.42% · BMM: -36.55%
3M Horizon HCM +61.46 pp
HCM: +8.54% · BMM: -52.92%
6M Horizon HCM +75.25 pp
HCM: +10.26% · BMM: -64.99%
1Y Horizon HCM +29.6 pp
HCM: -15.09% · BMM: -44.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HCM vs BMM. Trailing 12-month operating profitability (HCM -6.3% vs BMM N/A) and valuation multiples (HCM N/M vs BMM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HCM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$549M
Gross Margin13.3%
Op. Margin-6.3%
ROE / Fwd P/E1.5% · N/M
BMM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HCM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 82.7%
IV Percentile 73rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HCM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.3B market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment 19.6% of Rev ($108M)
90D Engineering Disclosures 0 Published
BMM Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HCM vs BMM Key Questions & Quantitative Answers

As of Nov 20, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over BMM (BMM) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HCM carries a Unified Composite Score of 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin), whereas BMM carries 38.2/100 (SELL) at $2.50 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although HCM compares more favorably head-to-head, both HCM (38.1/100 SELL) and BMM (38.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: HCM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.5); meanwhile BMM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HCM leads the Growth & Scale pillar: HCM posts +0.2% YoY revenue growth and -96.5% YoY earnings growth on $549M TTM revenue (13.3% gross margin, -6.3% operating margin), compared with BMM at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HCM generates $549M in USD-normalized revenue versus N/A for BMM. In operating R&D and SG&A reinvestment, HCM deploys 19.6% of Rev ($108M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMM.

HCM screens cheaper on headline valuation multiples. HCM trades at N/M Forward P/E, 134.0x Trailing P/E, N/M PEG, and 4.2x EV/Revenue (-3.7% EBITDA margin), whereas BMM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HCM (1.5% ROE) versus BMM (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, HCM carries 82.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.64β · 45% Vol realized risk). By comparison, BMM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.19β · 100% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.